Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis.

被引：3
|
作者：
Hatake, Kiyohiko
Kinoshita, Tomohiro
Fukuhara, Noriko
Choi, Ilseung
Taniwaki, Masafumi
Ando, Kiyoshi
Maruyama, Dai
Terui, Yasuhito
Higuchi, Yusuke
Onishi, Yasushi
Abe, Yasunobu
Kobayashi, Tsutomu
Shirasugi, Yukari
Tobinai, Kensei
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol & Oncol, Tokyo, Japan
[2] Aichi Canc Ctr, Dept Hematol & Cell Therapy, Nagoya, Aichi, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan
[4] Natl Hosp Org Kyushu Canc Ctr, Dept Hematol, Fukuoka, Japan
[5] Kyoto Prefectural Univ Med, Univ Hosp, Div Hematol & Oncol, Kyoto, Japan
[6] Tokai Univ, Dept Hematol & Oncol, Isehara, Kanagawa, Japan
[7] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e19018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19018
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Chen, Robert
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Klasa, Richard
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Kennedy, Dana A.
    Sievers, Eric L.
    Younes, Anas
    BLOOD, 2010, 116 (21) : 128 - 129
  • [22] Brentuximab Vedotin Plus Bendamustine in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Meta-Analysis
    Abdelgawad, Hussien Ahmed H.
    Belal, Mohamed Mohamed
    Bashir, Mohamed Nabih
    Aboeldahab, Heba
    Eshun, Francis
    Otto, Mario
    Henry, Michael
    BLOOD, 2023, 142
  • [23] A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination as Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
    Massaro, Fulvio
    Maerevoet, Marie
    Meuleman, Nathalie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S250 - S250
  • [24] Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Ishizawa, Kenichi
    Uike, Naokuni
    Uchida, Toshiki
    Suzuki, Tatsuya
    Aoki, Tomohiro
    Watanabe, Takashi
    Maruyama, Dai
    Yokoyama, Masahiro
    Takubo, Takatoshi
    Kagehara, Hideaki
    Matsushima, Takafumi
    CANCER SCIENCE, 2014, 105 (07) : 840 - 846
  • [25] A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination As Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
    Massaro, Fulvio
    Meuleman, Nathalie
    Bron, Dominique
    Maerevoet, Marie
    BLOOD, 2020, 136
  • [26] Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Song, Yuqin
    Guo, Ye
    Huang, Huiqiang
    Li, Wei
    Ke, Xiaoyan
    Feng, Jifeng
    Xu, Wei
    Miao, Harry
    Kinley, Judith
    Song, Gregory
    Dai, Yi
    Wang, Hui
    Zhu, Jun
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 867 - 875
  • [27] Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Chen, Lu
    Herrera, Alex F.
    Mei, Matthew
    McBride, Katrina
    Abary, Rosie
    Siddiqi, Tanya
    Popplewell, Leslie
    Forman, Stephen J.
    Rosen, Steven T.
    Kwak, Larry W.
    BLOOD, 2018, 132
  • [28] Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)
    Diefenbach, Catherine S.
    Gonzalez-Kozlova, Edgar
    Del Valle, Diane Marie
    Huang, Hsin-Hui
    Jegede, Opeyemi
    Barcessat, Vanessa
    Tuballes, Kevin
    Kelly, Geoffrey
    Patel, Manishkumar
    Xie, Hui
    Harris, Jocelyn
    Argueta, Kimberly
    Nie, Kai
    Moravec, Radim
    Altreuter, Jennifer
    Duose, Dzifa Yawa
    Kahl, Brad S.
    Ansell, Stephen M.
    Yu, Joyce
    Cerami, Ethan
    Lindsay, James
    Wistuba, Ignacio
    Kim-Schulze, Seunghee
    Gnjatic, Sacha
    BLOOD, 2023, 142
  • [29] Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Sievers, Eric L.
    Younes, Anas
    BLOOD, 2012, 120 (21)
  • [30] Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study
    Hagenbeek, Anton
    Zijlstra, Josee M.
    Plattel, Wouter J.
    Morschhauser, Franck
    Lugtenburg, Petronella J.
    Brice, Pauline
    Hutchings, Martin
    Gastinne, Thomas
    Liu, Roberto D.
    Burggraaf, Coreline N.
    Nijland, Marcel
    Tonino, Sanne H.
    van Tinteren, Harm
    Yurda, Marta I. Lopez
    Kersten, Marie Jose
    BLOOD, 2018, 132
12345